Sponsor or institution
Clinical trials and research at German CLL Study Group
As of November 12, 2026, Find a Trial lists 5 clinical trials run by German CLL Study Group that are recruiting, at sites in 5 countries (most in Germany (5), Austria (2), Denmark (2)). 1 was first registered in the last 30 days. By phase: Phase 2 (2), Phase 3 (1). Every study is explained in plain English. Data from ClinicalTrials.gov and NIH RePORTER, updated November 12, 2026.
- 5Clinical trials
- 1New in 30 days
- 5Countries
Newest trials
| Study | Phase | Where | Status | Registered |
|---|---|---|---|---|
| Pirtobrutinib and Epcoritamab vs R-(Mini)-CHOP for DLBCL-type Richter Transformation in older or frail adults | Phase 2 | Melbourne and 11 other locations | Recruiting | Nov 5, 2026 |
| Long-term survival after different first-line treatments for CLL | — | Cologne and 1 other locations | Recruiting | Jan 27, 2025 |
| Combination treatment for high-risk chronic lymphocytic leukemia | Phase 3 | Bad Saarow and 29 other locations | Recruiting | Jan 19, 2022 |
| Combining zanubrutinib and tislelizumab for treating Richter Transformation | Phase 2 | Vienna and 10 other locations | Recruiting | Feb 17, 2020 |
| Registry for patients with chronic lymphocytic leukemia and related conditions | — | Dresden, Saxony | Recruiting | Aug 11, 2016 |
All recruiting trials (5)
-
Pirtobrutinib and Epcoritamab vs R-(Mini)-CHOP for DLBCL-type Richter Transformation in older or frail adults
This trial tests a fixed-duration treatment with Pirtobrutinib and Epcoritamab against a mini-CHOP regimen in adults age 80+ or who are frail with Richter transformation.
-
Long-term survival after different first-line treatments for CLL
This follow-up will see if people with CLL who received different first-line treatments in GCLLSG trials live longer over time.
-
Combination treatment for high-risk chronic lymphocytic leukemia
This study is testing if a new combination of three drugs can help people with high-risk chronic lymphocytic leukemia live longer without their cancer getting worse compared to a combination of two drugs.
-
Combining zanubrutinib and tislelizumab for treating Richter Transformation
This study is testing a new combination of two drugs, zanubrutinib and tislelizumab, to see if they can help people with Richter Transformation, a serious complication of chronic lymphocytic leukemia, when other treatments haven't worked.
-
Registry for patients with chronic lymphocytic leukemia and related conditions
This study is tracking patients with chronic lymphocytic leukemia and similar conditions to see how well different treatments work and what long-term effects they might have.
Quick answers
How many clinical trials run by German CLL Study Group are recruiting right now?
5, as of November 12, 2026. 1 of them was first registered in the last 30 days. We update this list each time we refresh our data from ClinicalTrials.gov.
Where are these trials running?
In 5 countries. The most sites are in Germany (5 trials), Austria (2 trials), Denmark (2 trials), Australia (1 trial), Ireland (1 trial). Each study page lists its sites and which ones are recruiting.
What phases are they in?
Phase 2: 2, Phase 3: 1. Trials with no phase listed are usually device, behavioural or observational studies.
How do I join one?
Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.
Find the studies that fit you
A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.